Pub Date : 2008-11-01Epub Date: 2008-09-18DOI: 10.1016/j.rmedu.2008.08.004
Ivone Martins Ferreira
Chronic Obstructive Pulmonary disease (COPD) is associated with multiple comorbid conditions including ischemic heart disease, peripheral muscular dysfunction, osteoporosis, osteopenia, glaucoma, anemia, anxiety , depression, caquexia and malnutrition. A number of individuals with COPD experience involuntary weight loss as the condition progresses and weight loss, muscle wasting and tissue depletion are commonly seen.
Malnutrition has a negative impact on the clinical course of COPD. The negative impact of malnutrition has led to interest in nutritional assessment and supplementation, alone or in combination with anabolic substances or appetite stimulants, in an effort to improve disease outcome. The effects of nutritional supplementation on weigh gain and anthropometric parameters were small suggesting that oral supplementation alone is of limited efficacy. The studies with anabolic steroids or growth hormone showed improvement in nutritional parameters but no improvement in exercise capacity.
Large randomized trials that include measure of lean body mass, exercise capacity and quality of life should be stimulated.
{"title":"Up date nutritional support for patients with COPD","authors":"Ivone Martins Ferreira","doi":"10.1016/j.rmedu.2008.08.004","DOIUrl":"https://doi.org/10.1016/j.rmedu.2008.08.004","url":null,"abstract":"<div><p>Chronic Obstructive Pulmonary disease (COPD) is associated with multiple comorbid conditions including ischemic heart disease, peripheral muscular dysfunction, osteoporosis, osteopenia, glaucoma, anemia, anxiety , depression, caquexia and malnutrition. A number of individuals with COPD experience involuntary weight loss as the condition progresses and weight loss, muscle wasting and tissue depletion are commonly seen.</p><p>Malnutrition has a negative impact on the clinical course of COPD. The negative impact of malnutrition has led to interest in nutritional assessment and supplementation, alone or in combination with anabolic substances or appetite stimulants, in an effort to improve disease outcome. The effects of nutritional supplementation on weigh gain and anthropometric parameters were small suggesting that oral supplementation alone is of limited efficacy. The studies with anabolic steroids or growth hormone showed improvement in nutritional parameters but no improvement in exercise capacity.</p><p>Large randomized trials that include measure of lean body mass, exercise capacity and quality of life should be stimulated.</p></div>","PeriodicalId":101083,"journal":{"name":"Respiratory Medicine: COPD Update","volume":"4 4","pages":"Pages 127-131"},"PeriodicalIF":0.0,"publicationDate":"2008-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.rmedu.2008.08.004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91679359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2008-11-01Epub Date: 2008-09-19DOI: 10.1016/j.rmedu.2008.08.012
Nontypeable Haemophilus influenzae (NTHi) commonly colonizes the lower airways of patients with chronic obstructive pulmonary disease (COPD). Whether it contributes to COPD progression is unknown. Here, we determined which aspects of the COPD phenotype can be induced by repetitive exposure to NTHi products. Mice were exposed weekly to an aerosolized NTHi lysate, and inflammation was evaluated by measurement of cells and cytokines in bronchoalveolar lavage fluid (BALF) and immunohistochemical staining; structural changes were evaluated histochemically by periodic acid fluorescent Schiff's reagent, Masson's trichrome, and Picrosirius red staining; mucin gene expression was measured by quantitative RT-PCR; and the role of TNF-α was examined by transgenic airway overexpression and use of an inhibitory antibody. NTHi lysate induced rapid activation of NF-kappaB in airway cells and increases of inflammatory cytokines and neutrophils in BALF. Repetitive exposure induced infiltration of macrophages, CD8+ T cells, and B cells around airways and blood vessels, and collagen deposition in airway and alveolar walls, but airway mucin staining and gel-forming mucin transcripts were not increased. Transgenic overexpression of TNF-α caused BALF neutrophilia and inflammatory cell infiltration around airways, but not fibrosis, and TNF-α neutralization did not reduce BALF neutrophilia in response to NTHi lysate. In conclusion, NTHi products elicit airway inflammation in mice with a cellular and cytokine profile similar to that in COPD, and cause airway wall fibrosis but not mucous metaplasia. TNF-α is neither required for inflammatory cell recruitment nor sufficient for airway fibrosis. Colonization by NTHi may contribute to the pathogenesis of small airways disease in patients with COPD.
Reproduced with permission from the American Thoracic Society.
{"title":"A non-typeable Haemophilus influenzae (NTHi) causes COPD-like changes in mice","authors":"","doi":"10.1016/j.rmedu.2008.08.012","DOIUrl":"https://doi.org/10.1016/j.rmedu.2008.08.012","url":null,"abstract":"<div><p>Nontypeable Haemophilus influenzae (NTHi) commonly colonizes the lower airways of patients with chronic obstructive pulmonary disease (COPD). Whether it contributes to COPD progression is unknown. Here, we determined which aspects of the COPD phenotype can be induced by repetitive exposure to NTHi products. Mice were exposed weekly to an aerosolized NTHi lysate, and inflammation was evaluated by measurement of cells and cytokines in bronchoalveolar lavage fluid (BALF) and immunohistochemical staining; structural changes were evaluated histochemically by periodic acid fluorescent Schiff's reagent, Masson's trichrome, and Picrosirius red staining; mucin gene expression was measured by quantitative RT-PCR; and the role of TNF-<em>α</em> was examined by transgenic airway overexpression and use of an inhibitory antibody. NTHi lysate induced rapid activation of NF-kappaB in airway cells and increases of inflammatory cytokines and neutrophils in BALF. Repetitive exposure induced infiltration of macrophages, CD8+ T cells, and B cells around airways and blood vessels, and collagen deposition in airway and alveolar walls, but airway mucin staining and gel-forming mucin transcripts were not increased. Transgenic overexpression of TNF-<em>α</em> caused BALF neutrophilia and inflammatory cell infiltration around airways, but not fibrosis, and TNF-<em>α</em> neutralization did not reduce BALF neutrophilia in response to NTHi lysate. In conclusion, NTHi products elicit airway inflammation in mice with a cellular and cytokine profile similar to that in COPD, and cause airway wall fibrosis but not mucous metaplasia. TNF-<em>α</em> is neither required for inflammatory cell recruitment nor sufficient for airway fibrosis. Colonization by NTHi may contribute to the pathogenesis of small airways disease in patients with COPD.</p><p>Reproduced with permission from the American Thoracic Society.</p></div>","PeriodicalId":101083,"journal":{"name":"Respiratory Medicine: COPD Update","volume":"4 4","pages":"Page 138"},"PeriodicalIF":0.0,"publicationDate":"2008-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.rmedu.2008.08.012","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"137086984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2008-11-01Epub Date: 2008-09-19DOI: 10.1016/j.rmedu.2008.08.007
{"title":"Pulmonary rehabilitation works in elderly patients. Whether it works in all elderly COPD patients in the community remains an issue","authors":"","doi":"10.1016/j.rmedu.2008.08.007","DOIUrl":"https://doi.org/10.1016/j.rmedu.2008.08.007","url":null,"abstract":"","PeriodicalId":101083,"journal":{"name":"Respiratory Medicine: COPD Update","volume":"4 4","pages":"Page 133"},"PeriodicalIF":0.0,"publicationDate":"2008-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.rmedu.2008.08.007","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90007604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2008-11-01Epub Date: 2008-09-19DOI: 10.1016/j.rmedu.2008.08.013
Rationale
Although chronic obstructive pulmonary disease is the first indication for lung transplantation, the benefit of the procedure in terms of survival remains debated.
Objectives
To estimate the determinants of the survival benefit of lung transplantation in patients with chronic obstructive pulmonary disease.
Methods
Using information from the United Network for Organ Sharing database on 8182 patients, we developed an approach based on numerical simulations to estimate the survival effect of lung transplantation.
Measurements and main results
The main outcome measure was the difference between median survival with transplantation and that without transplantation measured from time of transplant list registration. Survival benefit was greater with double than with single lung transplantation (mean difference, 307 d [95% confidence interval, 217–523]). With double lung transplantation, 44.6% of patients would gain 1 year or more, 29.4% would gain or lose less than 1 year, and 26% would lose 1 year or more. Major determinants of the survival effect of transplantation were systolic pulmonary artery pressure, FEV1, body mass index, exercise capacity, functional status, and the need for continuous mechanical ventilation or oxygen. For instance, 79% of patients with an FEV1 less than 16% of the predicted value would gain 1 year or more with double lung transplantation as compared with only 11% of patients with an FEV1 of more than 25%.
Conclusions
We identified several factors associated with the survival benefit of lung transplantation. External validation of our models is required before translating these results into clinical practice.
Reproduced with permission from the American Thoracic Society.
理由:尽管慢性阻塞性肺疾病是肺移植的首要适应症,但就生存而言,该手术的益处仍存在争议。目的探讨慢性阻塞性肺疾病患者肺移植生存获益的影响因素。方法利用美国器官共享网络(United Network for Organ Sharing)数据库中8182例患者的信息,建立了一种基于数值模拟的方法来评估肺移植的生存效果。测量指标和主要结果主要结果测量指标是移植后中位生存期与未移植后中位生存期的差异,从移植名单登记时开始测量。双肺移植的生存获益大于单肺移植(平均差异为307天[95%可信区间,217-523])。双肺移植患者生存期1年及以上的占44.6%,生存期1年及以下的占29.4%,生存期1年及以上的占26%。影响移植生存效果的主要因素是肺动脉收缩压、FEV1、体重指数、运动能力、功能状态以及持续机械通气或供氧的需要。例如,在FEV1低于预测值16%的患者中,79%的患者可以通过双肺移植获得1年或更长时间,而FEV1大于25%的患者中只有11%。结论:我们确定了与肺移植的生存获益相关的几个因素。在将这些结果转化为临床实践之前,需要对我们的模型进行外部验证。经美国胸科学会许可转载。
{"title":"What is the survival benefit in COPD from lung transplantation?","authors":"","doi":"10.1016/j.rmedu.2008.08.013","DOIUrl":"10.1016/j.rmedu.2008.08.013","url":null,"abstract":"<div><h3>Rationale</h3><p>Although chronic obstructive pulmonary disease is the first indication for lung transplantation, the benefit of the procedure in terms of survival remains debated.</p></div><div><h3>Objectives</h3><p>To estimate the determinants of the survival benefit of lung transplantation in patients with chronic obstructive pulmonary disease.</p></div><div><h3>Methods</h3><p>Using information from the United Network for Organ Sharing database on 8182 patients, we developed an approach based on numerical simulations to estimate the survival effect of lung transplantation.</p></div><div><h3>Measurements and main results</h3><p>The main outcome measure was the difference between median survival with transplantation and that without transplantation measured from time of transplant list registration. Survival benefit was greater with double than with single lung transplantation (mean difference, 307<!--> <!-->d [95% confidence interval, 217–523]). With double lung transplantation, 44.6% of patients would gain 1 year or more, 29.4% would gain or lose less than 1 year, and 26% would lose 1 year or more. Major determinants of the survival effect of transplantation were systolic pulmonary artery pressure, FEV<sub>1</sub>, body mass index, exercise capacity, functional status, and the need for continuous mechanical ventilation or oxygen. For instance, 79% of patients with an FEV<sub>1</sub> less than 16% of the predicted value would gain 1 year or more with double lung transplantation as compared with only 11% of patients with an FEV<sub>1</sub> of more than 25%.</p></div><div><h3>Conclusions</h3><p>We identified several factors associated with the survival benefit of lung transplantation. External validation of our models is required before translating these results into clinical practice.</p><p>Reproduced with permission from the American Thoracic Society.</p></div>","PeriodicalId":101083,"journal":{"name":"Respiratory Medicine: COPD Update","volume":"4 4","pages":"Page 139"},"PeriodicalIF":0.0,"publicationDate":"2008-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.rmedu.2008.08.013","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75784868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2008-11-01Epub Date: 2008-09-19DOI: 10.1016/j.rmedu.2008.08.009
{"title":"Tiotropium is better than ipratropium at reducing exacerbations, hospital referrals and hospital admissions in patients in general practice","authors":"","doi":"10.1016/j.rmedu.2008.08.009","DOIUrl":"https://doi.org/10.1016/j.rmedu.2008.08.009","url":null,"abstract":"","PeriodicalId":101083,"journal":{"name":"Respiratory Medicine: COPD Update","volume":"4 4","pages":"Page 135"},"PeriodicalIF":0.0,"publicationDate":"2008-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.rmedu.2008.08.009","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"137007166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2008-11-01Epub Date: 2008-09-19DOI: 10.1016/j.rmedu.2008.08.019
{"title":"Pulmonary rehabilitation: Greatest benefit for those who live alone?","authors":"","doi":"10.1016/j.rmedu.2008.08.019","DOIUrl":"https://doi.org/10.1016/j.rmedu.2008.08.019","url":null,"abstract":"","PeriodicalId":101083,"journal":{"name":"Respiratory Medicine: COPD Update","volume":"4 4","pages":"Page 143"},"PeriodicalIF":0.0,"publicationDate":"2008-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.rmedu.2008.08.019","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90015198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}